Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 10/20 | 0.46 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA9 | Q16790 | 10/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | MAP3K12 | Q12852 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532184 | 0.91 | PIK3CA (0.75) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL533270 | 0.85 | PIK3CA (0.83) | PIK3CAMTORJAK2 | |
| SCHEMBL2121280 | 0.81 | PIK3CA (0.57) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL3513049 | 0.78 | PIK3CA (0.59) | PIK3CAMTORMAP3K12JAK2 | |
| SCHEMBL532388 | 0.77 | PIK3CA (0.50) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL532339 | 0.77 | PIK3CA (0.70) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL15961348 | 0.77 | PIK3CA (0.49) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL533129 | 0.77 | PIK3CA (0.71) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL532032 | 0.76 | PIK3CA (0.68) | PIK3CACA12CA1CA2CA9 | |
| SCHEMBL532183 | 0.76 | PIK3CA (1.00) | PIK3CAMTORKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | claimed |
| EP-2414369-B1 | IMIDAZO[2,1-B][1,3,4]THIADIAZOLE DERIVATIVES | FUNDACIÓN CT NAC DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (ES) | 2015-08-12 | — | — | EP | disclosed |
| US-8815918-B2 | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2014-08-26 | — | — | US | disclosed |
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2414369-A1 | IMIDAZO [2, 1-B][ 1, 3, 4]THIADIAZOLE DERIVATIVES | Centro Nacional de Investigaciones Oncológicas (CNIO) (ES) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010112874-A1 | IMIDAZO [2, 1-B] [ 1, 3, 4 ] THIADIAZOLE DERIVATIVES | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094996-A1 | Imidazo [2, 1-B] [1, 3, 4] Thiadiazole Derivatives | PIK3CA, PI4KA, PIK3CD | PIK3CA 1/4885CA12 4737/4885CA1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.